CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13-11-2018
FDA lifts hold on first human CRISPR trial
17-10-2018
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14-12-2017
Sergey Nivens / Shutterstock.com
US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Vertex Pharmaceuticals, CRISPR Therapeutics, CRISPR Cas-9, cystic fibrosis, sickle cell disease, royalties,
